Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
01:15am, Thursday, 16'th Oct 2025
Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhal
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
07:30am, Friday, 10'th Oct 2025
Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX sh
Here's Why Novartis (NVS) is a Strong Value Stock
10:41am, Wednesday, 08'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
09:46am, Wednesday, 08'th Oct 2025
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
3 Reasons Growth Investors Will Love Novartis (NVS)
01:46pm, Monday, 06'th Oct 2025
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 06'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Advanz Pharma Holdco Limited and Alvotech announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®? . Alvotech
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 06'th Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2 Surefire Dividend Stocks to Buy for the Long Haul
09:37am, Saturday, 04'th Oct 2025
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
08:56am, Friday, 03'rd Oct 2025
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
10:16am, Thursday, 02'nd Oct 2025
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with
US FDA approves Novartis' drug for skin disease
04:22pm, Tuesday, 30'th Sep 2025
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled di
